-DOCSTART- -X- O
This -X- _ O
review -X- _ O
examines -X- _ O
the -X- _ O
small -X- _ O
molecules -X- _ O
described -X- _ O
over -X- _ O
the -X- _ O
past -X- _ O
decade -X- _ O
as -X- _ O
inhibitors -X- _ O
of -X- _ O
any -X- _ O
of -X- _ O
the -X- _ O
approximately -X- _ O
100 -X- _ B-Patient
human -X- _ I-Patient
deubiquitinating -X- _ I-Patient
enzymes -X- _ I-Patient
( -X- _ I-Patient
DUBs -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
Structures -X- _ O
from -X- _ O
patent -X- _ O
publications -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
from -X- _ O
the -X- _ O
primary -X- _ O
literature -X- _ O
are -X- _ O
included. -X- _ O
Inhibitors -X- _ B-Intervention
of -X- _ I-Intervention
two -X- _ I-Intervention
viral -X- _ I-Intervention
DUBs -X- _ I-Intervention
are -X- _ O
also -X- _ O
described -X- _ O
since -X- _ O
these -X- _ B-Outcome
proteases -X- _ I-Outcome
share -X- _ I-Outcome
structural -X- _ I-Outcome
similarity -X- _ I-Outcome
with -X- _ I-Outcome
one -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
human -X- _ I-Outcome
DUB -X- _ I-Outcome
sub-families. -X- _ I-Outcome
The -X- _ O
structure -X- _ O
, -X- _ O
function -X- _ O
and -X- _ O
disease -X- _ O
associations -X- _ O
of -X- _ O
certain -X- _ O
DUBs -X- _ O
are -X- _ O
presented. -X- _ O
The -X- _ O
evolution -X- _ O
of -X- _ O
the -X- _ O
screening -X- _ O
assays -X- _ O
used -X- _ O
to -X- _ O
identify -X- _ O
and -X- _ O
characterise -X- _ O
new -X- _ O
inhibitors -X- _ O
is -X- _ O
discussed. -X- _ O
Several -X- _ O
emerging -X- _ O
trends -X- _ O
in -X- _ O
the -X- _ O
series -X- _ O
are -X- _ O
highlighted -X- _ O
and -X- _ O
the -X- _ O
‘drug-likeness’ -X- _ O
of -X- _ O
the -X- _ O
various -X- _ O
inhibitors -X- _ O
is -X- _ O
analysed. -X- _ O
Large -X- _ O
pharmaceutical -X- _ O
company -X- _ O
collaborations -X- _ O
have -X- _ O
drawn -X- _ O
attention -X- _ O
to -X- _ O
this -X- _ O
field -X- _ O
, -X- _ O
and -X- _ O
these -X- _ O
recent -X- _ O
advances -X- _ O
are -X- _ O
discussed -X- _ O
in -X- _ O
the -X- _ O
context -X- _ O
of -X- _ O
the -X- _ O
wider -X- _ O
range -X- _ O
of -X- _ O
therapeutically -X- _ O
important -X- _ O
DUB -X- _ O
targets -X- _ O
. -X- _ O

